ClinicalTrials.gg
Active, not recruitingNCT05791708CADENCEUpdated Apr 22, 2026

Cold Agglutinin Disease Real World Evidence Registry

An observational study in Cold Agglutinin Disease (CAD) and Cold Agglutinin Syndrome (CAS), sponsored by RECORDATI GROUP. Active, not recruiting at 68 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by RECORDATI GROUP · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
429
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States — 4 open to participants now, 9 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · United States.

Started
2019
with 3 others
Observational
Only one
of the 31
Registered
27th of 31
by date

Among the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, this one is one of 4 that started in 2019, is the only observational one, and was the 27th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

4 of the 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Hemolytic, Autoimmune with a site in United States, or all of them as a file.
02

Study summary

This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347396], and BIVV009-04/EFC16216 [NCT03347422]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry.

03

Conditions studied

  • Cold Agglutinin Disease (CAD)
  • Cold Agglutinin Syndrome (CAS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with CAD or CAS will be eligible, regardless of the type of CAD or CAS-specific therapy they are receiving. In addition, the Cadence registry will include a sutimlimab cohort study whose objective is to assess the safety and the effectiveness of sutimlimab in patients with CAD in a real-world setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged ≥18 years
  2. Patient able to understand the purpose of the study and who (or whose legally authorized representative) provided signed and dated and authorization to use protected health information in accordance with national and local subject privacy regulations
  3. Patient with a diagnosis of CAD or CAS as per Investigator judgment based on the diagnosis criteria listed in study protocol

Exclusion criteria

Exclusion Criteria:

  1. Patient with mixed warm and cold hemolytic anemia, or warm autoimmune hemolytic anemia
  2. Patient actively participating in a CAD or CAS interventional clinical trial. After a patient completes participation in said trial, he/she may be eligible for enrollment in this registry.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
429 participants (actual)
Target follow-up
6 Years
Patient registry
Yes

Groups and cohorts

  • cold agglutinin disease (CAD)

    Patient with a diagnosis of CAD as per investigator judgment based on the diagnosis criteria listed in study protocol. In addition, this group includes a cohort of CAD patients treated with sutimlimab

    Drug: Sutimlimab

  • cold agglutinin syndrome (CAS)

    Patient with a diagnosis of CAS as per investigator judgment based on the diagnosis criteria listed in study protocol

Interventions

  • CAD patients in Sutimlimab cohort must be treated according to routine clinical practice

06

What researchers measure

Primary outcomes

  1. Patterns of CAD and CAS disease characteristics

    CAD or CAS characteristics at diagnosis, enrollment, and during follow up (e.g., criteria used for diagnosis, symptoms, laboratory results) will be described.

    Time frame: Up to 6 years

  2. Number of participants with CAD or CAS complications

    Thromboembolic events (venous, arterial or cerebral), deaths related to CAD or CAS, other CAD/CAS complications (e.g., acute hemolytic crisis, hemolysis-related complications), and other comorbid conditions occurring before enrollment, at enrollment, and during follow up will be described.

    Time frame: Up to 6 years

  3. Patterns of use of CAD and CAS treatments

    CAD or CAS treatments received before enrollment, at enrollment, and during the follow up period will be summarized. CAD or CAS symptoms and complications, autoimmune disorders or lymphoproliferative disorders, physician assessment of treatment status, and changes in laboratory results will be described by CAD or CAS treatments.

    Time frame: Up to 6 years

  4. Number of participants with health-resource utilization

    Health resource utilization may include hospitalizations (including length of stay), outpatient visits, emergency room visits, specific transfusion visits, nursing home/rehabilitation center stays, and home healthcare visits during registry follow-up period

    Time frame: Up to 6 years

  5. Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD-SIQ)

    Time frame: Up to 6 years

  6. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

    Time frame: Up to 6 years

  7. 36-Item Short Form Survey Instrument (SF-36) v2

    Time frame: Up to 6 years

  8. Sutimlimab cohort: Sutimlimab treatment patterns

    Sutimlimab dosing information, reasons for dose adjustments, reasons for discontinuation will be described.

    Time frame: Up to 6 years

  9. Sutimlimab cohort: Number of participants with adverse events, serious adverse events, adverse events of special interests (AESIs), other events of interests (e.g., Treatment emergent)

    Time frame: Up to 6 years

  10. Sutimlimab cohort: change from baseline in hemoglobin

    Time frame: From baseline up to 6 years

  11. Sutimlimab cohort: change from baseline in bilirubin

    Time frame: From baseline up to 6 years

  12. Sutimlimab cohort: change from baseline in Lactate dehydrogenase (LDH)

    Time frame: From baseline up to 6 years

  13. Sutimlimab cohort: number of blood cells transfusions

    Time frame: Up to 6 years

07

Study locations

68 sites
  • University of Alabama at Birmingham Site Number : 1230
    Birmingham, Alabama 35205, United States
  • SLO Oncology and Hematology Site Number : 1235
    San Luis Obispo, California 93401, United States
  • Mission Hope Medical Oncology Site Number : 1241
    Santa Maria, California 93454, United States
  • MedStar Georgetown University Hospital / Lombardi Comprehensive Cancer Center Site Number : 1208
    Washington D.C., District of Columbia 20007, United States
  • Piedmont Cancer Institute, P.C Site Number : 1226
    Atlanta, Georgia 30290, United States
  • Orchard Heathcare Research Inc. Site Number : 1202
    Skokie, Illinois 60077, United States
  • Siouxland Regional Cancer Center dba June E. Nylen Cancer Center Site Number : 1220
    Sioux City, Iowa 51101, United States
  • Reliant Medical Group Site Number : 1205
    Worcester, Massachusetts 01608, United States
  • Henry Ford Hospital Site Number : 1232
    Detroit, Michigan 48202, United States
  • Northwell Health-Monter Cancer Center-North Shore University Hospital and Steven and Alexandra Cohen Children's Medical Center of New York (Schneider Children's Hospital)-North Shore Long Island Jewis Site Number : 1231
    Lake Success, New York 11042, United States
  • Center for Blood Disorders Site Number : 1214
    New York, New York 10021, United States
  • SUNY Upstate Medical University Site Number : 1221
    Syracuse, New York 13210, United States
  • Brody School of Medicine at East Carolina University Site Number : 1203
    Greenville, North Carolina 27834, United States
  • Cleveland Clinic Foundation Site Number : 1207
    Cleveland, Ohio 44195, United States
  • The Ohio State University Site Number : 1236
    Columbus, Ohio 43210, United States
  • Hematology Oncology Associates, PC Site Number : 1211
    Medford, Oregon 97504, United States
  • University of Pittsburgh Medical Center-UPMC Hillman Cancer Center Site Number : 1210
    Pittsburgh, Pennsylvania 15232, United States
  • UT Medical Center Cancer Institute Site Number : 1237
    Knoxville, Tennessee 37920, United States
  • University of Washingtion Seattle Cancer Care Alliance Site Number : 1238
    Seattle, Washington 98109, United States
  • Investigational Site Number : 3101
    Salzburg, 5020, Austria
  • Investigational Site Number : 3102
    Vienna, 1090, Austria
  • Investigational Site Number : 3222
    Amiens, 80054, France
  • Investigational Site Number : 3214
    Angers, 49933, France
  • Investigational Site Number : 3204
    Cesson-Sévigné, 35510, France
  • Investigational Site Number : 3211
    Chalon-sur-Saône, 71100, France
  • Investigational Site Number : 3206
    Corbeil-Essonnes, 91100, France
  • Investigational Site Number : 3201
    Créteil, 94010, France
  • Investigational Site Number : 3219
    Dijon, 21079, France
  • Investigational Site Number : 3221
    Epagny-Metz-Tessy, 74370, France
  • Investigational Site Number : 3217
    Paris, 75013, France
  • Investigational Site Number : 3213
    Pau, 64000, France
  • Investigational Site Number : 3203
    Pessac, 33600, France
  • Investigational Site Number : 3216
    Poitiers, 86021, France
  • Investigational Site Number : 3202
    Quimper, 2900, France
  • Investigational Site Number : 3220
    Rennes, 35033, France
  • Investigational Site Number : 3205
    Saint-Priest-en-Jarez, 42270, France
  • Investigational Site Number : 3218
    Toulouse, 31059, France
  • Investigational Site Number : 3301
    Essen, 45147, Germany
  • Investigational Site Number : 3306
    Hanover, 30161, Germany
  • Investigational Site Number : 3302
    Landshut, 84036, Germany
  • Investigational Site Number : 3413
    Brescia, Lombardy 25123, Italy
  • Investigational Site Number : 3410
    Campobasso, 86100, Italy
  • Investigational Site Number : 3403
    Novara, 28100, Italy
  • Investigational Site Number : 3411
    Palermo, 90146, Italy
  • Investigational Site Number : 3415
    Pavia, 27100, Italy
  • Investigational Site Number : 3412
    Ravenna, 48121, Italy
  • Investigational Site Number : 3402
    Reggio Calabria, 89133, Italy
  • Investigational Site Number : 3404
    Roma, 00161, Italy
  • Investigational Site Number : 3405
    Terni, 05100, Italy
  • Investigational Site Number : 2203
    Fukushima, Fukushima 960-1295, Japan
  • Investigational Site Number : 2204
    Himeji-shi, Hyōgo 670-0063, Japan
  • Investigational Site Number : 3701
    Barcelona, Barcelona [Barcelona] 8036, Spain
  • Investigational Site Number : 3712
    Madrid, 28034, Spain
  • Investigational Site Number : 3603
    Truro, Cornwall TR13LJ, United Kingdom
  • Investigational Site Number : 3617
    Carlisle, Cumbria CA2 7HY, United Kingdom
  • Investigational Site Number : 3608
    Gillingham, Kent ME75NY, United Kingdom
  • Investigational Site Number : 3605
    London, London, City of NW1 2PG, United Kingdom
  • Investigational Site Number : 3602
    Salford, Manchester M6 8HD, United Kingdom
  • Investigational Site Number : 3623
    Airdrie, North Lanarkshire ML60JS, United Kingdom
  • Investigational Site Number : 3601
    Newcastle upon Tyne, North Tyneside NE29 8NH, United Kingdom
  • Investigational Site Number : 3613
    Middlesbrough, North Yorkshire TS4 3BW, United Kingdom
  • Investigational Site Number : 3611
    Oxford, Oxfordshire OX3 7LE, United Kingdom
  • Investigational Site Number : 3606
    Taunton, Somerset TA1 5DA, United Kingdom
  • Investigational Site Number : 3618
    Birmingham, B15 2GW, United Kingdom
  • Investigational Site Number : 3620
    Harrow, HA1 3UJ, United Kingdom
  • Investigational Site Number : 3612
    Leeds, LS9 7TF, United Kingdom
  • Investigational Site Number : 3607
    Liverpool, L7 8XP, United Kingdom
  • Investigational Site Number : 3621
    London, E1 2ES, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2019 (actual). Primary completion is estimated for Nov 2028, 106 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Mar 30, 2023
StartActual
Dec 12, 2019
Primary completionEst.
Nov 2, 2028
CompletionEst.
Nov 2, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05791708
Lead sponsor
RECORDATI GROUP
Responsible party
Sponsor
First posted
Mar 30, 2023
Start date
Dec 12, 2019
Primary completion
Nov 2, 2028 (estimated)
Completion
Nov 2, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Ignacio Alvarez Rojo
study director · RECORDATI GROUP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion